Oxidant stress and regulation of chemokines in the development of renal interstitial fibrosis

Contributions to Nephrology

Volumn 139, Issue , 2003, Pages 102-119

  Cochrane, Anita L ^a   Ricardo, Sharon D ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; REACTIVE OXYGEN METABOLITE;

ANIMAL; CHRONIC KIDNEY FAILURE; DISEASE COURSE; DISEASE MODEL; GLOMERULUS; HUMAN; IMMUNOLOGY; INTERSTITIAL NEPHRITIS; MACROPHAGE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; CHEMOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; MACROPHAGES; NEPHRITIS, INTERSTITIAL; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 0141888076     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000071739     Document Type: Article

References (105)

1. Eddy AA: Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 1994;5:1273-1287.
2. Nikolic-Paterson DJ, Lan HY, Hill PA, Atkins RC: Macrophages in renal injury. Kidney Int Suppl 1994;45:S79-S82.
3. Schreiner GF, Harris KP, Purkerson ML, Klahr S: Immunological aspects of acute ureteral obstruction: Immune cell infiltrate in the kidney. Kidney Int 1988;34:487-493.
4. Nikolic-Paterson DJ, Lan HY, Hill PA, Atkins RC: Macrophages in renal injury. Kidney Int Suppl 1994;45:S79-S82.
5. Schreiner GF: The role of the macrophages in glomerular injury. Semin Nephrol 1991;11:268-275.
6. Yang N, Isbel NM, Nikolic-Paterson DJ, Li Y, Ye R, Atkins RC, Lan HY: Local macrophage proliferation in human glomerulonephritis. Kidney Int 1998;54:143-151.
7. Uesugi N, Sakata N, Horiuchi S, Nagai R, Takeya M, Meng J, Saito T, Takebayashi S: Glycoxidation-modified macrophages and lipid peroxidation products are associated with the progression of human diabetic nephropathy. Am J Kidney Dis 2001;38:1016-1025.
8. Eddy AA, Ho GC, Thorner PS: The contribution of antibody-mediated cytotoxicity and immunecomplex formation to tubulointerstitial disease in passive Heymann nephritis. Clin Immunol Immunopathol 1992;62:42-55.
9. 1, granulocyte-macrophage colony-stimulating factor, interleukin-2 and interleukin-10. Transplantation 1995;59:565-572.
10. Truong LD, Farhood A, Tasby J, Gillum D: Experimental chronic renal ischemia: Morphologic and immunologic studies. Kidney Int 1992;41:1676-1689.
11. Takahashi H, Calvet JP, Dittemore-Hoover D, Yoshida K, Grantham JJ, Gattone VH 2nd: A hereditary model of slowly progressive polycystic kidney disease in the mouse. J Am Soc Nephrol 1991;1:980-989.
12. Jones CL, Buch S, Post M, McCulloch L, Liu E, Eddy AA: Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats. Am J Pathol 1992;141:1381-1396.
13. Saito T, Atkins RC: Contribution of mononuclear leucocytes to the progression of experimental focal glomerular sclerosis. Kidney Int 1990;37:1076-1083.
14. Eddy AA: Tubulointerstitial nephritis during the heterologous phase of nephrotoxic serum nephritis. Nephron 1991;59:304-313.
15. Van Goor H, van der Horst ML, Fidler V, Grond J: Glomerular macrophage modulation affects mesangial expansion in the rat after renal ablation. Lab Invest 1992;66:564-571.
16. Wu LL, Yang N, Roe CJ, Cooper ME, Gilbert RE, Atkins RC, Lan HY: Macrophage and myofibroblast proliferation in remnant kidney: Role of angiotensin II. Kidney Int Suppl 1997;63:S221-S225.
17. Ziyadeh FN, Goldfarb S: The renal tubulointerstitium in diabetes mellitus. Kidney Int 1991;39:464-475.
18. Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser WG, Seidel K: Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 1995;47:935-944.
19. Sato N, Shiraiwa K, Kai K, Watanabe A, Ogawa S, Kobayashi Y, Yamagishi-Imai H, Utsunomiya Y, Mitarai T: Mizoribine ameliorates the tubulointerstitial fibrosis of obstructive nephropathy. Nephron 2001;89:177-185.
20. Feng L, Chen S, Garcia GE, Xia Y, Siani MA, Botti P, Wilson CB, Harrison JK, Bacon KB: Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. Kidney Int 1999;56:612-620.
21. Romero F, Rodriguez-Iturbe B, Parra G, Gonzalez L, Herrera-Acosta J, Tapia E: Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999;55:945-955.
22. Yokoyama H, Wada T, Furuichi K: Chemokines in renal fibrosis; Razzaque MS, Taguchi T (eds): Renal Fibrosis. Contrib Nephrol. Basel, Karger 2003, vol 139, pp 66-89.
23. Klahr S: New insights into the consequences and mechanisms of renal impairment in obstructive nephropathy. The modulation of macrophage migration and eicosanoid metabolism. Am J Kidney Dis 1991;18:689-699.
24. Kato S, Luyckx VA, Ots M, Lee KW, Ziai F, Troy JL, Brenner BM, MacKenzie HS: Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 1999;56:1037-1048.
25. Kelly DJ, Wilkinson-Berka JL, Ricardo SD, Cox AJ, Gilbert RE: Progression of tubulointerstitial injury by osteopontin-induced macrophage recruitment in advanced diabetic nephropathy of transgenic (mRen-2)27 rats. Nephrol Dial Transplant 2002;17:985-991.
26. Ketteler M, Border WA, Noble NA: Cytokines and L-arginine in renal injury and repair. Am J Physiol 1994;267:F197-F207.
27. Hibbs JB Jr, Taintor RR, Vavrin Z, Rachlin EM: Nitric oxide: A cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988;157:87-94.
28. Xia Y, Zweier JL: Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc Natl Acad Sci USA 1997;94:6954-6958.
29. Klebanoff SJ: Oxygen metabolites from phagocytes; in Gallin J, Goldstein I, Snyderman R (eds): Inflammation: Basic Principles and Clinical Correlates. New York, Raven Press, 1992, pp 541-588.
30. Diamond JR, Kees-Folts D, Ricardo SD, Pruznak A, Eufemio M: Early and persistent up-regulated expression of renal cortical osteopontin in experimental hydronephrosis. Am J Pathol 1995;146:1455-1466.
31. Denhardt DT, Guo X: Osteopontin: A protein with diverse functions. FASEB J 1993;7:1475-1482.
32. Giachelli CM, Steitz S: Osteopontin: A versatile regulator of inflammation and biomineralization. Matrix Biol 2000;19:615-622.
33. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F: Expression, roles, receptors and regulation of osteopontin in the kidney. Kidney Int 2001;10:1645-1657.
34. Giachelli CM, Pichler R, Lombardi D, Denhardt DT, Alpers CE, Schwartz SM, Johnson RJ: Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int 1994;45:515-524.
35. Ricardo SD, Franzoni DF, Roesener CD, Crisman JM, Diamond JR: Angiotensinogen and AT1 antisense inhibition of osteopontin translation in rat proximal tubular cells. Am J Physiol 2000;278:F708-F716.
36. Wolf G: Angiotensin II is involved in the progression of renal disease: Importance of nonhemodynamic mechanisms. Nephrologie 1998;19:451-456.
37. Park YS, Guijarro C, Kim Y, Massy ZA, Kasiske BL, Keane WF, O'Donnell MP: Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 1998;31:190-194.
38. Cowley BD Jr, Ricardo SD, Nagao S, Diamond JR: Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD. Kidney Int 2001;60:2087-2096.
39. 1 and monocyte chemotactic protein-1 expression induced by cyclosporin in human mesangial cells. Clin Exp Immunol 1999;117:355-360.
40. Suganami T, Mukoyama M, Sugawara A, Mori K, Nagae T, Kasahara M, Yahata M, Makino H, Fujinaga Y, Ogawa Y, Tanaka I, Nakao K: Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. J Am Soc Nephrol 2001;12:2652-2663.
41. Mezzano SA, Barria M, Droguett MA, Burgos ME, Ardiles LG, Flores C, Egido J: Tubular NF-κB and AP-1 activation in human proteinuric renal disease. Kidney Int 2001;60:1366-1377.
42. Taal MW, Chertow GM, Rennke HG, Gurani A, Jiang T, Shahsafaei A, Troy JL, Brenner BM: Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am J Physiol 2001;280:F343-F355.
43. Grandaliano G, Gesualdo L, Bartoli F, Ranieri E, Monno R, Leggio A, Paradies G, Caldarulo E, Infante B, Schena FP: MCP-1 and EGF renal expression ad urine excretion in human congenital obstructive nephropathy. Kidney Int 2000;58:182-192.
44. Klahr S: Urinary tract obstruction. Semin Nephrol 2001;21:133-145.
45. Vielhauer V, Anders HJ, Mack M, Cihak J, Strutz F, Stangassinger M, Luckow B, Grone HJ, Schlondorff D: Obstructive nephropathy in the mouse: Progressive fibrosis correlates with tubulointerstitial chemokine expression and accumulation of CC chemokine receptor 2- and 5-positive leukocytes. J Am Soc Nephrol 2001;12:1173-1187.
46. Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, Hamouda W, Dandona P: Suppression of nuclear factor κβ and stimulation of inhibitor κβ by troglitazone: Evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001;86:1306-1312.
47. Schwarz M, Wahl M, Resch K, Radeke HH: IFN-γ induces functional chemokine receptor expression in human mesangial cells. Clin Exp Immunol 2002;128:285-294.
48. Wang Y, Rangan GK, Tay YC, Wang Y, Harris DC: Induction of monocyte chemoattractant protein-1 by albumin is mediated by nuclear factor κB in proximal tubular cells. J Am Soc Nephrol 1999;10:1204-1213.
49. Schlondorff D: The role of chemokines in the initiation and progression of renal disease. Kidney Int 1995;47:S44-S47.
50. Sato E, Simpson KL, Grisham MB, Koyama S, Robbins RA: Effects of reactive oxygen and nitrogen metabolites on MCP-1-induced monocyte chemotactic activity in vitro. Am J Physiol 1999;277:L543-L549.
51. Rohrmoser MM, Mayer G: Reactive oxygen species and glomerular injury. Kidney Blood Press Res 1996;19:263-269.
52. Mathur S, Devaraj S, Jialal I: Accelerated atherosclerosis, dyslipidemia and oxidant stress in endstage renal disease. Curr Opin Nephrol Hypertens 2002;11:141-147.
53. Trachtman H, Chan JC, Chan W, Valderrama E, Brandt R, Wakely P, Futterweit S, Maesaka J, Ma C: Vitamin E ameliorates renal injury in an experimental model of immunoglobulin A nephropathy. Pediatr Res 1996;40:620-626.
54. Scheinman JI, Trachtman H, Lin CY, Langman CB, Chan JC: IgA nephropathy: To treat or not to treat? Nephron 1997;75:251-258.
55. Imaeda A, Kaneko T, Aoki T, Kondo Y, Nagase H: DNA damage and the effect of antioxidants in streptozotocin-treated mice. Food Chem Toxicol 2002;40:979-987.
56. Evans JL, Heymann CJ, Goldfine ID, Gavin LA: Pharmokinetics, tolerability and fructosaminelowering effect of a novel, controlled-release formulation of α-lipoic acid. Endocr Pract 2002;8:29-35.
57. Schackenberg CG: Oxygen radicals in cardiovascular-renal disease. Curr Opin Pharmacol 2002;2:121-125.
58. Satyanarayana PS, Singh D, Chopra K: Quercetin, a bioflavanoid, protects against oxidative stressrelated renal dysfunction by cyclosporine in rats. Methods Findings Exp Clin Pharmacol 2001;23:175-181.
59. Takaoka M, Ohkita M, Kobayashi Y, Yuba M, Matsumura Y: Protective effect of α-lipoic acid against ischaemic acute renal failure in rats. Clin Exp Pharmacol Physiol 2002;29:189-194.
60. Davis ID, MacRae Dell K, Sweeney WE, Avner ED: Can progression of autosomal dominant or autosomal recessive polycystic kidney disease be prevented? Semin Nephrol 2001;21:430-440.
61. 1 and collagen gene expression. Kidney Int 1998;53: 367-381.
62. Ricardo SD, Diamond R: The role of macrophages and reactive oxygen species in experimental hydronephrosis. Semin Nephrol 1998;18:612-621.
63. Kinter M, Wolstenholme JT, Thornhill BA, Newton EA, McCormick ML, Chevalier RL: Unilateral ureteral obstruction impairs renal antioxidant enzyme activation during sodium depletion. Kidney Int 1999;55:1327-1334.
64. Ricardo SD, Ding G, Eufemio M, Diamond J: Antioxidant expression in experimental hydronephrosis: Role of mechanical stretch and growth factors. Am J Physiol 1997;272:F789-F798.
65. Modi KS, Morrissey J, Shah SV, Schreiner GF, Klahr S: Effects of probucol on renal function in rats with bilateral ureteral obstruction. Kidney Int 1990;38:843-850.
66. Wautier MP, Chappey O, Lorda S, Stern DM, Schmidt AM, Wautier SL: Activation of NADPH oxidation by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol 2001;280:E685-E694.
67. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW: Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. J Biol Chem 2000;275:21177-21184.
68. Yaqoob M, McClelland P, Patrick AW, Stevenson A, Mason H, White MC, Bell GM: Evidence of oxidant injury and tubular damage in early diabetic nephropathy. Q J Med 1994;87:601-607.
69. Loven D, Schedl H, Wilson H, Daabees TT, Stegink LD, Diekus M, Oberley L: Effect of insulin and oral glutathione on glutathione levels and superoxide dismutase activities in organs of rats with streptozotocin-induced diabetes. Diabetes 1986;35:503-507.
70. Kowluru RA, Tang J, Kern TS: Abnormalities of retinal metabolism in diabetes and experimental alactosemia. Diabetes 2001;50:1938-1949.
71. Wautier MP, Chappey O, Lorda S, Stern DM, Schmidt AM, Wautier SL: Activation of NADPH oxidation by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol 2001;280:E685-E694.
72. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW: Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. J Biol Chem 2000;275:21177-21184.
73. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
74. Nishikawa T, Edelstein D, Liang XD, Yamagishi SI, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Browlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 2000;404:787-790.
75. Palmer HJ, Paulson KE: Reactive oxygen species and antioxidants in signal transduction and gene expression. Nutr Rev 1997;55:353-361.
76. Lander HM: An essential role for free radicals in signal transduction. FASEB J 1997;11:118-124.
77. Sorescu D, Griendling KK: Reactive oxygen species, mitochondria and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail 2002;8:132-140.
78. 11(I) gene expression in cultured human fibroblasts. Modulation of constitutive collagen gene expression by lipid peroxidation. J Clin Invest 1991;87:2230-2235.
79. Park SK, Kim J, Seomun Y, Choi J, Kim DH, Han IO, Lee EH, Chung SK, Joo CK: Hydrogen peroxide is a novel inducer of connective tissue growth factor. Biochem Biophys Res Commun 2001;284:966-971.
80. Dominguez-Rosales JA, Mavi G, Levenson SM, Rojkind M: H2O2 is an important mediator of physiological and pathological healing processes. Arch Med Res 2000;31:15-20.
81. Hannken T, Schroeder R, Stahl RAK, Wolf G: Angiotensin II-mediated expression of p27kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Kidney Int 2002;54:1923-1933.
82. Haugen EN, Croatt AJ, Nath KA: Angiotensin II induced renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro. Kidney Int 2000;58:144-152.
83. Hannken T, Schroeder R, Zahner G, Stahl RAK, Wolf G: Reactive oxygen species stimulate p44/42 mitogen-activated protein kinase and induce p27kip1:role in angiotensin II-mediated hypertrophy of proximal tubular cells. J Am Soc Nephrol 2000;11:1387-1397.
84. Hoerrner, LA, Kowalski AJ, Diamond JR, Wilson PA, Denhardt DT: Homeostatic and pathological action of nitric oxide in the kidney; in Laskin JD, Laskin DL (eds): Cellular and Molecular Biology of Nitric Oxide. Basel, Karger, 1999, pp 137-169.
85. Radi R, Peluffo G, Alvarez MN, Naviliat M, Cayota A: Unravelling peroxynitrite formation in biological systems. Free Radic Biol Med 2001;30:463-488.
86. Beckman JS, Koppenol WH: Nitric oxide, superoxide and peroxynitrite: The good, the bad, and ugly. Am J Physiol 1996;271:C1424-C1437.
87. Ahn KY, Mohaupt MG, Madsen KM, Kone BC: In situ hybridization localization of mRNA encoding inducible nitric oxide synthase in rat kidney. Am J Physiol 1994;267:F748-F757.
88. Morrissey JJ, McCracken R, Kaneto H, Vehaskari M, Montani D, Klahr S: Location of an inducible nitric oxide synthase mRNA in the normal kidney. Kidney Int 1994;45:998-1005.
89. Muhl H, Sandau K, Brune B, Briner VA, Pfeilschifter J: Nitric oxide donors induce apoptosis in glomerular mesangial cells, epithelial cells and endothelial cells. Eur J Pharmacol 1996;317:137-149.
90. Amore A, Emancipator SN, Cirina P, Conti G, Ricotti E, Bagheri N, Coppo R: Nitric oxide mediates cyclosporine-induced apoptosis in cultured renal cells. Kidney Int 2000;57:1549-1559.
91. Bank N, Kiroycheva M, Ahmed F, Anthony GM, Fabry ME, Nagel RL, Singhal PC: Peroxynitrite formation and apoptosis in transgenic sickle cell mouse kidneys. Kidney Int 1998;54:1520-1528.
92. Pryor WA, Squadrito GL: The chemistry of peroxynitrite: A product from the reaction of nitric oxide with superoxide. Am J Physiol 1995;268:L699-L722.
93. Ischiropoulos H: Biological tyrosine nitration: A pathophysiological function of nitric oxide and reactive oxygen species. Arch Biochem Biophys 1998;356:1-11.
94. Zhang C, Walker LM, Mayeux PR: Role of nitric oxide in lipopolysaccharide-induced oxidant stress in the rat kidney. Biochem Pharmacol 2000;59:203-209.
95. Goligorsky MS, Brodsky SV, Noiri E: Nitric oxide in acute renal failure: NOS versus NOS. Kidney Int 2002;61:855-861.
96. Traylor LA, Mayeux PR: Superoxide generation by renal proximal tubule nitric oxide synthase. Nitric Oxide 1997;1:432-438.
97. Heeringa P, van Goor H, Moshage H, Klok PA, Huitema MG, de Jager A, Schep AJ, Kallenberg CG: Expression of iNOS, eNOS and peroxynitrite-modified proteins in experimental anti-myeloperoxidaseassociated crescentic glomerulonephritis. Kidney Int 1998;53:382-393.
98. Heeringa P, Steenbergen E, van Goor H: A protective role for endothelial nitric oxide synthase in glomerulonephritis. Kidney Int 2002;61:822-825.
99. Zhou XJ, Laszik Z, Wang XQ, Silva FG, Vaziri ND: Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosidersosis. Lab Invest 2000;80:1905-1914.
100. Thuraisingham RC, Nott CA, Dodd SM, Yaqoob MM: Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy. Kidney Int 2000;57:1968-1972.
101. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS: Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002;61:186-194.
102. Zykova SN, Jenssen TG, Berdal M, Olsen R, Myklebust R, Seljelid R: Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice. Diabetes 2000;49:1451-1458.
103. Tannous M, Rabini RA, Vignini A, Moretti N, Fumelli P, Zielinski B, Mazzanti L, Mutus B: Evidence for iNOS-dependent peroxynitrite production in diabetic platelets. Diabetologia 1999;42:539-544.
104. Sharma K, Danoff TM, DePiero A, Ziyadeh FN: Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: Possible mediation via protein kinase C. Biochem Biophys Res Commun 1995;207:80-88.
105. Ishii N, Patel KP, Lane PH, Taylor T, Bian K, Murad F, Pollock JS, Carmines PK: Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus. J Am Soc Nephrol 2001;12:1630-1639.